SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1000)4/30/2001 11:12:38 AM
From: rkrw  Respond to of 3158
 
<<5. Failing Biotechs

Finally, when all else fails, you flutter your eyes at all eligible suitors and exclaim how very cheap you somehow happen to be. FOCL is the latest example.>>

AGEN munching ARNX 2 weeks ago is another classic example.
AGEN has now done two such acquisition: AQLA and now ARNX.



To: Biomaven who wrote (1000)4/30/2001 12:26:23 PM
From: nigel bates  Read Replies (1) | Respond to of 3158
 
How about :

6. "Genomics" companies who announced they were getting into drug discovery, but now realise they can acquire a reasonable program for less than the annual interest on their cash pile...



To: Biomaven who wrote (1000)4/30/2001 1:48:46 PM
From: dalroi  Respond to of 3158
 
k here is me list
maxy
lexg dgen
cvas
nbix
celg
sepr

stefaan



To: Biomaven who wrote (1000)4/30/2001 4:12:08 PM
From: nigel bates  Respond to of 3158
 
How about -

6. Merger of near equals to achieve critical mass

A la Curis. Might belong under

5 b. Drunks propping each other up

however.



To: Biomaven who wrote (1000)5/1/2001 12:42:48 PM
From: jayhawk969  Read Replies (1) | Respond to of 3158
 
Peter,

And the SI cool post of the day goes to>>>>>>>>>>>>

Congragulations,

J.D.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News